JP2023511331A5 - - Google Patents
Info
- Publication number
- JP2023511331A5 JP2023511331A5 JP2022543677A JP2022543677A JP2023511331A5 JP 2023511331 A5 JP2023511331 A5 JP 2023511331A5 JP 2022543677 A JP2022543677 A JP 2022543677A JP 2022543677 A JP2022543677 A JP 2022543677A JP 2023511331 A5 JP2023511331 A5 JP 2023511331A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antibody
- sequence shown
- cdr1
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062961768P | 2020-01-16 | 2020-01-16 | |
| US62/961,768 | 2020-01-16 | ||
| PCT/US2021/013423 WO2021146413A1 (en) | 2020-01-16 | 2021-01-14 | Humanized antibodies specific for myeloma and ovarian cancer cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023511331A JP2023511331A (ja) | 2023-03-17 |
| JP2023511331A5 true JP2023511331A5 (cg-RX-API-DMAC10.html) | 2024-01-22 |
Family
ID=76864708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022543677A Pending JP2023511331A (ja) | 2020-01-16 | 2021-01-14 | 骨髄腫細胞および卵巣がん細胞に特異的なヒト化抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230138520A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4090433A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023511331A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20220129044A (cg-RX-API-DMAC10.html) |
| CA (1) | CA3167936A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021146413A1 (cg-RX-API-DMAC10.html) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6376654B1 (en) * | 1999-08-13 | 2002-04-23 | Molecular Discoveries, Llc | Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof |
| US7226750B1 (en) * | 2000-08-08 | 2007-06-05 | Molecular Discoveries, Inc. | Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof |
| AU2002368077B2 (en) * | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| JP2010526066A (ja) * | 2007-04-23 | 2010-07-29 | シェーリング コーポレイション | 抗ｍｄｌ−１抗体 |
| EP2246364A1 (en) * | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anti CXCR4 antibodies for the treatment of HIV |
| US20130089554A1 (en) * | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| WO2016040767A2 (en) * | 2014-09-12 | 2016-03-17 | Amgen Inc. | Chrdl-1 epitopes and antibodies |
| JP6749589B2 (ja) * | 2015-07-31 | 2020-09-02 | 国立大学法人北海道大学 | 抗Ｅｖａ１タンパク質抗体 |
| EP3443006B1 (en) * | 2016-04-13 | 2023-08-02 | Sanofi | Trispecific and/or trivalent binding proteins |
| WO2020150402A2 (en) * | 2019-01-15 | 2020-07-23 | Caerus Therapeutics, Corp. | Advanced chimeric antigen receptor vectors for targeting solid tumors |
-
2021
- 2021-01-14 WO PCT/US2021/013423 patent/WO2021146413A1/en not_active Ceased
- 2021-01-14 JP JP2022543677A patent/JP2023511331A/ja active Pending
- 2021-01-14 CA CA3167936A patent/CA3167936A1/en active Pending
- 2021-01-14 EP EP21741822.7A patent/EP4090433A4/en not_active Withdrawn
- 2021-01-14 US US17/793,603 patent/US20230138520A1/en not_active Abandoned
- 2021-01-14 KR KR1020227028311A patent/KR20220129044A/ko active Pending